Crohn’s Disease News and Research

RSS

Small is beautiful in the medical world

Small is beautiful in the medical world. And being able to give European industry the edge in a nearly €200 billion worldwide biomedical market is what drives a consortium of EU-backed partners to make and market smaller, cheaper and better biomedical devices and innovative new applications.

19 Jan 2005

New findings clarify the role of NOD2, a key molecular player in Crohn's Disease

This week, researchers report new findings that clarify the role of NOD2, a key molecular player in Crohn's Disease, in the cellular signaling pathways that control inflammatory responses. NOD2's clinical relevance is clear from the fact that it is encoded by a Crohn's Disease susceptibility gene.

28 Dec 2004

Parasitic worms, or helminths, may be an effective treatment for Crohn's disease

Helminths, such as roundworms and threadworms, are rare in developed countries, where rates of Crohn's disease are high. But in developing countries where corresponding rates of the disease are low, many people carry these parasitic worms.

13 Dec 2004

FDA approval of Tysabri, for the treatment of multiple sclerosis

Biogen and Elan Corporation have announced that the U.S. Food and Drug Administration (FDA) has approved Tysabri (natalizumab), as treatment for relapsing forms of multiple sclerosis (MS) to reduce the frequency of clinical relapses.

24 Nov 2004

Abbott's investigational anti-interleukin-12 fully human monoclonal antibody in Crohn's disease study

Results of a Phase II study of Abbott's ABT-874, a fully human anti-interleukin-12 (IL-12) monoclonal antibody, will appear tomorrow in the New England Journal of Medicine citing treatment with ABT-874 shows differences in response and remission in patients with active Crohn's disease compared to placebo, in one arm of the study.

10 Nov 2004

New studies demonstrate efficacy of novel Lipoxin analog in laboratory models of Crohn's disease

Berlex announced today that new laboratory results demonstrate that its modified version of the naturally occurring lipoxin molecule exerts potent anti-inflammatory and immunomodulatory effects in Crohn's disease in vivo models and may provide a promising new oral treatment.

9 Nov 2004

Analysis shows Remicade reduces pain associated with Crohn's disease

According to a new sub-analysis from the ACCENT I (A Crohn's disease Clinical trial Evaluating infliximab in a New long-term Treatment regimen) trial patients who received a three-dose induction regimen of Remicade experienced a significantly greater reduction in pain as assessed by four different pain questions after ten weeks, compared with patients who received a single dose of Remicade.

2 Nov 2004

New research points to potential new treatments for sickle cell disease

New research from the University of North Carolina at Chapel Hill reveals why red blood cells from people with sickle cell disease are stickier than healthy red cells, pointing the way to potential new treatments for sickle cell disease.

12 Oct 2004

New oral gel used instead of injection to deliver drugs

Scientists in India have developed a new gel that is taken orally and is capable of delivering drugs to manage diseases often requiring an injection.

20 Sep 2004

Crohn’s disease may be caused by same bacterium that causes Paratuberculosis or Johne’s disease in cattle, sheep, and goats

A study in this week’s issue of THE LANCET suggests that Crohn’s disease may be caused by Mycobacterium avium subspecies paratuberculosis (MAP), the same bacterium that causes a similar intestinal disorder (known as Paratuberculosis or Johne’s disease) in cattle, sheep, and goats.

17 Sep 2004

Genetically modified bacterium as remedy for intestinal diseases

Researchers from the Flanders Interuniversity Institute for Biotechnology (VIB) at Ghent University are joining the fight against chronic intestinal disease with a genetically modified bacterium (Lactococcus lactis).

14 Sep 2004

60 percent of people with Crohn's disease have required surgery within the past five years

According to results released today from the newest survey of people with Crohn's disease, "Voices of Crohn's," 60 percent of people with Crohn's, between the ages of 18 and 34, have been hospitalized within the last two years and more than half have required surgery within the past five years.

18 Aug 2004

New pill-size camera travels beyond other scope procedures to reveal gastrointestinal disorders in small intestines that often go unseen

If it doesn't sound like your typical disposable camera, that's because it's not. And while this new camera is not designed to snap shots during vacations or at other special occasions, patients are finding that the latest in high-tech, digital photography is very easy to swallow.

9 Aug 2004

Unique dual laparoscopic surgical procedure

The skill and teamwork of two physicians at Scripps Clinic, combined with the expertise of the surgical staff at Scripps Green Hospital, recently led to a unique surgery that changed the life of a local woman.

21 Jul 2004

New risk factors associated with inflammatory bowel disease

Health researchers at the Christchurch School of Medicine and Health Sciences, Otago University, have found evidence of new risk factors associated with a debilitating illness called Inflammatory Bowel Disease (IBD).

24 Jun 2004

Crohn's disease and ulcerative colitis patients to rally in Washington

The Crohn's & Colitis Foundation of America (CCFA) is traveling to Washington, DC June 14th-15th to build support for legislation aimed at better understanding, preventing and curing Crohn's disease and ulcerative colitis.

11 Jun 2004

Helminthic therapy, using worm eggs to treat patients with inflammatory bowel disorders

University of Iowa Health Care researchers reported important findings recently at a conference of specialists in New Orleans, La. The findings are from their study of helminthic therapy - using specially prepared worm eggs - to treat patients diagnosed with inflammatory bowel disorders that don't respond to standard treatments.

21 May 2004

Accurate and effective new methods for diagnosis of Inflammatory bowel diseases

Inflammatory bowel diseases collectively cause significant lifestyle sacrifices and suffering and millions of dollars in related health care costs every year, partially due to a lack of effective diagnostic procedures and therapies. In new studies presented today at Digestive Disease Week in New Orleans, researchers show evidence of accurate and effective new methods for diagnosis, as well as improved treatment options, for sufferers of ulcerative colitis and Crohn’s diseases.

19 May 2004

Study comparing the efficacy of REMICADE® to Azathioprine alone and in combination With REMICADE®

Centocor, Inc., and Schering-Plough Corporation announced today the initiation of the SONIC (Study of Immunomodulator Naive patients in Crohn's Disease) trial that will evaluate the efficacy of REMICADE® (infliximab) versus azathioprine, a conventional immunosuppressive agent, alone and versus the combination of both drugs for the treatment of patients with Crohn's disease.

18 May 2004

Researchers receive almost £1 million in funding for Irritable Bowel Syndrome

Researchers at The University of Nottingham, England have picked up almost £1 million in funding for a number of studies into a painful and distressing bowel condition that will affect up to one in 10 of the population at some time or another.

11 May 2004